
Sarclisa approved in Japan for newly diagnosed multiple myeloma
The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ Phase III study. Olivier Nataf, Global Head of Oncology at Sanofi,… Read More















